France Daily Times
SEE OTHER BRANDS

Your daily news update on France

France Daily Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on France Daily Times.

Press releases published on September 23, 2025

Ex-PUMA Chief Sourcing Officer Anne-Laure Descours Joins Haelixa Board
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Credence MedSystems and SMC Ltd. Pharma Services Announce Collaboration to Advance Dual Chamber Fill-Finish Capabilities
Enamine joins forces with the ICR to expand fragment-based drug discovery with fluorinated compound libraries
Dassault Aviation Inaugurates New Facility
Inauguration d’une nouvelle usine Dassault Aviation
Facephi technology for HancomWith secures Good Software (GS), top-level certification for public sector deployment in South Korea
La tecnología de Facephi para HancomWith obtiene la certificación Good Software (GS) de máximo nivel para su despliegue en el sector público de Corea del Sur
한컴위드에 적용된 페이스피 (FacePhi) 기술, 한국 공공 부문 도입에 필요한 최고 수준의 굿소프트웨어(GS) 인증 획득
STARLight Project chosen as the European consortium to take the lead in next-generation Silicon Photonics on 300mm wafers
ABC arbitrage: HY 2025 Consolidated Results
ABC arbitrage : Résultat consolidé S1 20251
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Communiqué de presse : La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions